Form 4: United Therapeutics CFO Executes Stock Option Plan

CFO James Edgemond exercised 10,000 stock options and sold the resulting shares under a pre-established Rule 10b5-1 trading plan.

Summary

• CFO and Treasurer James Edgemond exercised 10,000 stock options at a strike price of $135.42.
• Following the exercise, the reporting person sold 10,000 shares of common stock in multiple tranches.
• The sales occurred at weighted average prices ranging from $565.85 to $571.92 per share.
• The transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted on October 31, 2025.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the transaction was pre-planned and represents standard executive financial management.

Positives

• The transaction was executed under a pre-planned Rule 10b5-1 trading plan, indicating the sales were not based on non-public information.
• The exercise of options demonstrates the executive's participation in the company's long-term equity incentive program.

Negatives

• The transaction results in a reduction of the CFO's direct beneficial ownership of company stock.

Risks

• None identified in this specific Form 4 filing.

Future Outlook

No forward-looking guidance provided in this filing.

Industry Context

StockSavvy.ai notes that routine insider selling under 10b5-1 plans is a standard corporate governance practice for executives to manage personal liquidity and is generally viewed as neutral by the market.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for executives at major biotech firms like Amgen or Gilead to avoid potential insider trading allegations.

Stakeholder Impact

• Minimal impact on shareholders as the transaction was conducted via a pre-arranged plan.

Next Steps

• No future actions or milestones mentioned.

Key Dates

Keywords

United Therapeutics, UTHR, Insider Trading, Form 4, CFO, Stock Options, Rule 10b5-1